Harm Reduction

The Model Addressing Drug Diversion in Healthcare Settings Act (Act) (1) requires healthcare entities to establish policies and procedures for the prevention and detection of drug diversion by healthcare professionals and to ensure that treatment and recovery support services are offered to eligible healthcare professionals; (2) requires certain individuals and entities to report healthcare professionals suspected of misusing drugs and/or alcohol, diverting drugs for personal use, having an untreated substance use disorder, or practicing while impaired and to establish penalties for failure to make such reports; (3) requires boards, as defined in this Act, to establish or participate in an alternative to discipline program for eligible healthcare professionals; (4) establishes legal protections for individuals who make reports as required by this Act; (5) provides immunity from civil and criminal liability for specified individuals and entities for actions taken pursuant to this Act; (6) establishes penalties for healthcare entities that fail to take corrective action after discovering diversion by a healthcare professional; (7) establishes program reporting and audit requirements; (8) establishes technology grants for healthcare entities to be used for the prevention and detection of drug diversion; and (9) establishes funding provisions for alternative to discipline programs....

Psilocybin is a chemical compound produced by more than 100 species of mushrooms found growing around the world. Because of the psychedelic effects that these mushrooms produce when consumed, psilocybin-containing mushrooms have been colloquially referred to as “magic mushrooms” or “shrooms.” In this document, the Legislative Analysis and Public Policy Association (LAPPA) identifies both currently-in-force statutes/regulations and recently proposed legislation related to psilocybin throughout all 50 states, the District of Columbia, and the U.S. territories....

Given the increased emphasis in recent years on using harm reduction strategies to slow the overdose crisis, the hurdle posed by state drug paraphernalia laws to freely allowing drug checking services or establishing syringe services programs is not inconspicuous. Accordingly, in 2022, LAPPA first undertook an extensive research project to determine how drug paraphernalia laws throughout the 50 states, District of Columbia, and all U.S. territories treat drug checking equipment (including fentanyl test strips and other items) and needles/syringes. This January 2024 version, which sets forth a summary of state and territory laws as of December 2023, is an update to the original report. ...

Through the use of medications for addiction treatment (MAT), an individual’s substance use, withdrawal symptoms, and the physiological and psychological cravings can be controlled, enabling the person to begin treatment while in a correctional facility and be released as a person in, or on his or her way to, recovery. Research shows that that the use of MAT for Opioid Use Disorder in correctional settings is a cost-effective and life-saving intervention....

In this document, the Legislative Analysis and Public Policy Association examines state-level legislative and administrative responses to the public health risk posed by expired and unused prescription medications. In the last several years, states, in coordination with the Federal Drug Enforcement Administration (DEA) have enacted legislation or promulgated administrative regulations to authorize drug take-back programs where expired or unused pharmaceuticals can be collected from the public by authorized persons and disposed of in a safe manner. Findings are presented by state for ease of comparison....

Syringe services programs (SSP) are harm reduction programs that provide a wide range of services including, but not typically limited to, the provision of new, unused hypodermic needles and syringes and other injection drug use supplies, such as cookers, tourniquets, alcohol wipes, and sharps waste disposal containers, to people who inject drugs. In this summary, readers will find information with respect to SSPs for each state, including citations to applicable statutes and/or regulations, whether the state allows SSPs by statute, whether there are any municipal or county ordinances or regulations in place within the state, program components, miscellaneous provisions, and information on any pending legislation....

In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) details how opioid settlement proceeds are being disbursed to state and local governments, how those governments are choosing to spend those funds, and the obstacles that can prevent these funds from helping those who have been affected by the opioid epidemic....

In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) provides an overview of the sudden increase in the presence of BTMPS in the illicit drug supply and its rapid proliferation across the country, which has left drug policy experts and harm reduction specialists puzzled as to why it is in the supply and how it will affect the individuals consuming it....

To complement the opioid prescribing guidelines that the University of Buffalo Department of Emergency Medicine established in 2016, Dr. Joshua Lynch developed the Medication for Addiction Treatment and Electronic Referrals (MATTERS) program. He saw the need for MATTERs because the “window of opportunity” to help someone with a substance use disorder is small, and he wanted to immediately link a patient who had overdosed to a treatment program that is right for that individual....